[开放获取]    慢性瘙痒管理指南（2024版）

doi:10.35541/cjd.20230746

Abstract

Abstract: 【Abstract】 Chronic pruritus is a common symptom of various diseases, causing severe negative impacts on patients′ quality of life. Due to its complex pathogenesis, etiological diagnosis and treatment are often challenging. To improve the understanding of chronic pruritus among Chinese clinicians and to standardize diagnosis and therapeutic practices, the China Dermatologist Association organized experts in China to update the classification, etiology, and pathogenesis of chronic pruritus based on the "Guidelines for the Management of Chronic Pruritus （2018 edition）" , current research status and progress in China and other countries, as well as extensive consultation with experts in China through the Delphi method, aiming to provide expert opinions and evidence-based medical guidance on the etiological diagnosis and treatment of chronic pruritus.

Key words: Pruritus, Diagnosis, Therapeutics, Case management, Chronic pruritus, Etiology, Guideline

China Dermatologist Association. Guidelines for the management of chronic pruritus （2024）[J]. Chinese Journal of Dermatology, 2024, 57(5): 387-399.doi:10.35541/cjd.20230746

References ［113］

［1］	Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch［J］. Nat Rev Neurosci, 2006,7（7）:535⁃547. doi: 10.1038/nrn1950.
［2］	中国医师协会皮肤科分会变态反应性疾病专业委员会. 慢性瘙痒管理指南（2018版）［J］. 中华皮肤科杂志, 2018,51（7）:481⁃485. doi: 10.3760/cma.j.issn.0412⁃4030.2018.07.001.
［3］	Mack MR, Kim BS. The itch⁃scratch cycle: a neuroimmune perspective［J］. Trends Immunol, 2018,39（12）:980⁃991. doi: 10.1016/j.it.2018.10.001.
［4］	Ständer S, Zeidler C, Augustin M, et al. S2k guideline: diagnosis and treatment of chronic pruritus［J］. J Dtsch Dermatol Ges, 2022,20（10）:1387⁃1402. doi: 10.1111/ddg.14830.
［5］	Matterne U, Strassner T, Apfelbacher CJ, et al. Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large⁃scale studies［J］. Acta Derm Venereol, 2009,89（3）:250⁃256. doi: 10.2340/00015555⁃0641.
［6］	Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity［J］. Acta Derm Venereol, 2009,89（4）:339⁃350. doi: 10.2340/00015555⁃0662.
［7］	Dalgard F, Lien L, Dalen I. Itch in the community: associations with psychosocial factors among adults［J］. J Eur Acad Dermatol Venereol, 2007,21（9）:1215⁃1219. doi: 10.1111/j.1468⁃3083.2007.02234.x.
［8］	Matterne U, Apfelbacher CJ, Vogelgsang L, et al. Incidence and determinants of chronic pruritus: a population⁃based cohort study［J］. Acta Derm Venereol, 2013,93（5）:532⁃537. doi: 10.2340/00015555⁃1572.
［9］	Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross⁃sectional study in a sample working population of 11,730［J］. Dermatology, 2010,221（3）:229⁃235. doi: 10.1159/000319862.
［10］	Ju Y, Pei H, Kang N, et al. Prevalence and potential risk factors of chronic pruritus among community middle⁃aged and older population in Beijing, China［J］. J Eur Acad Dermatol Venereol, 2022,36（7）:1074⁃1079. doi: 10.1111/jdv.18041.
［11］	Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus: a population⁃based cross⁃sectional study［J］. Acta Derm Venereol, 2011,91（6）:674⁃679. doi: 10.2340/00015555⁃1159.
［12］	Yosipovitch G, Goon AT, Wee J, et al. Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus［J］. Int J Dermatol, 2002,41（4）:212⁃216. doi: 10.1046/j.1365⁃4362.2002.01460.x.
［13］	Szepietowski JC, Salomon J. Uremic pruritus: still an important clinical problem［J］. J Am Acad Dermatol, 2004,51（5）:842⁃843. doi: 10.1016/j.jaad.2004.04.003.
［14］	Akolo C, Ukoli CO, Ladep GN, et al. The clinical features of HIV/AIDS at presentation at the Jos University Teaching Hospital［J］. Niger J Med, 2008,17（1）:83⁃87. doi: 10.4314/njm.v17i1.37363.
［15］	Mazeh D, Melamed Y, Cholostoy A, et al. Itching in the psychiatric ward［J］. Acta Derm Venereol, 2008,88（2）:128⁃131. doi: 10.2340/00015555⁃0406.
［16］	Dalgard FJ, Svensson Å, Halvorsen JA, et al. Itch and mental health in dermatological patients across Europe: a cross⁃sectional study in 13 countries［J］. J Invest Dermatol, 2020,140（3）:568⁃573. doi: 10.1016/j.jid.2019.05.034.
［17］	Tripathi R, Knusel KD, Ezaldein HH, et al. The cost of an itch: a nationally representative retrospective cohort study of pruritus⁃associated health care expenditure in the United States［J］. J Am Acad Dermatol, 2019,80（3）:810⁃813. doi: 10.1016/j.jaad.2018.10.025.
［18］	Chen XJ, Sun YG. Central circuit mechanisms of itch［J］. Nat Commun, 2020,11（1）:3052. doi: 10.1038/s41467⁃020⁃16859⁃5.
［19］	Wang F, Yang TB, Kim BS. The return of the mast cell: new roles in neuroimmune itch biology［J］. J Invest Dermatol, 2020,140（5）:945⁃951. doi: 10.1016/j.jid.2019.12.011.
［20］	Saini SS, Kaplan AP. Chronic spontaneous urticaria: the Devil′s itch［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1097⁃1106. doi: 10.1016/j.jaip.2018.04.013.
［21］	Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch［J］. Cell, 2017,171（1）:217⁃228.e13. doi: 10.1016/j.cell.2017.08.006.
［22］	Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: involvement of TRPV1 and TRPA1［J］. J Allergy Clin Immunol, 2014,133（2）:448⁃460. doi: 10.1016/j.jaci.2013.10.048.
［23］	Dehner C, Chen L, Kim B, et al. Chronic itch of unknown origin is associated with an enhanced Th2 skin immune profile［J］. Am J Dermatopathol, 2021,43（11）:773⁃775. doi: 10.1097/DAD. 0000000000001902.
［24］	Wang F, Trier AM, Li F, et al. A basophil⁃neuronal axis promotes itch［J］. Cell, 2021,184（2）:422⁃440.e17. doi: 10.1016/j.cell.2020.12.033.
［25］	Liu B, Tai Y, Achanta S, et al. IL⁃33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy［J］. Proc Natl Acad Sci U S A, 2016,113（47）:E7572⁃E7579. doi: 10.1073/pnas.1606608113.
［26］	Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch⁃associated responses in mice［J］. Eur J Pharmacol, 1998,353（1）:93⁃96. doi: 10.1016/s0014⁃2999（98）00440⁃3.
［27］	Meixiong J, Vasavda C, Snyder SH, et al. MRGPRX4 is a G protein⁃coupled receptor activated by bile acids that may contribute to cholestatic pruritus［J］. Proc Natl Acad Sci U S A, 2019,116（21）:10525⁃10530. doi: 10.1073/pnas.1903316116.
［28］	Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid⁃induced itch and analgesia［J］. J Clin Invest, 2013,123（4）:1513⁃1530. doi: 10.1172/JCI64551.
［29］	Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron⁃specific GPCR Mrgprs are itch receptors mediating chloroquine⁃induced pruritus［J］. Cell, 2009,139（7）:1353⁃1365. doi: 10.1016/j.cell.2009.11.034.
［30］	Lin Z, Chen Q, Lee M, et al. Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome［J］. Am J Hum Genet, 2012,90（3）:558⁃564. doi: 10.1016/j.ajhg.2012.02.006.
［31］	Zhao J, Munanairi A, Liu XY, et al. PAR2 mediates itch via TRPV3 signaling in keratinocytes［J］. J Invest Dermatol, 2020,140（8）:1524⁃1532. doi: 10.1016/j.jid.2020.01.012.
［32］	Akiyama T, Tominaga M, Takamori K, et al. Roles of glutamate, substance P, and gastrin⁃releasing peptide as spinal neurotransmitters of histaminergic and nonhistaminergic itch［J］. Pain, 2014,155（1）:80⁃92. doi: 10.1016/j.pain.2013.09.011.
［33］	Sun YG, Chen ZF. A gastrin⁃releasing peptide receptor mediates the itch sensation in the spinal cord［J］. Nature, 2007,448（7154）:700⁃703. doi: 10.1038/nature06029.
［34］	Mishra SK, Hoon MA. The cells and circuitry for itch responses in mice［J］. Science, 2013,340（6135）:968⁃971. doi: 10.1126/science.1233765.
［35］	Carstens EE, Carstens MI, Simons CT, et al. Dorsal horn neurons expressing NK⁃1 receptors mediate scratching in rats［J］. Neuroreport, 2010,21（4）:303⁃308. doi: 10.1097/WNR.0b013e328337310a.
［36］	Kim BS, Inan S, Ständer S, et al. Role of kappa⁃opioid and mu⁃opioid receptors in pruritus: peripheral and central itch circuits［J］. Exp Dermatol, 2022,31（12）:1900⁃1907. doi: 10.1111/exd.14669.
［37］	Zhao ZQ, Liu XY, Jeffry J, et al. Descending control of itch transmission by the serotonergic system via 5⁃HT1A⁃facilitated GRP⁃GRPR signaling［J］. Neuron, 2014,84（4）:821⁃834. doi: 10.1016/j.neuron.2014.10.003.
［38］	Mu D, Sun YG. Circuit mechanisms of itch in the brain［J］. J Invest Dermatol, 2022,142（1）:23⁃30. doi: 10.1016/j.jid.2021. 09.022.
［39］	Auyeung KL, Jenkins BA, Kim BS. Clinical management of neuropathic itch［J］. JAMA Dermatol, 2023,159（12）:1391⁃1392. doi: 10.1001/jamadermatol.2023.3384.
［40］	Lepping P, Huber M, Freudenmann RW. How to approach delusional infestation［J］. BMJ, 2015,350:h1328. doi: 10.1136/bmj.h1328.
［41］	Pereira MP, Farcas A, Zeidler C, et al. Chronic pruritus of unknown origin: clinical profile and disease⁃related burden［J］. Acta Derm Venereol, 2021,101（9）:adv00550. doi: 10.2340/00015555⁃3892.
［42］	Erickson S, Kim BS. Research techniques made simple: itch measurement in clinical trials［J］. J Invest Dermatol, 2019,139（2）:264⁃269.e1. doi: 10.1016/j.jid.2018.12.004.
［43］	Yosipovitch G, Gooderham MJ, Ständer S, et al. Interpreting the relationship among itch, sleep, and work productivity in patients with moderate⁃to⁃severe atopic dermatitis: a post hoc analysis of JADE MONO⁃2［J］. Am J Clin Dermatol, 2024,25（1）:127⁃138. doi: 10.1007/s40257⁃023⁃00810⁃7.
［44］	Krajnik M, Zylicz Z. Pruritus in advanced internal diseases. Pathogenesis and treatment［J］. Neth J Med, 2001,58（1）:27⁃40. doi: 10.1016/s0300⁃2977（00）00084⁃x.
［45］	Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T⁃cell lymphoma: a review［J］. J Am Acad Dermatol, 2012,67（4）:760⁃768. doi: 10.1016/j.jaad.2011.12.021.
［46］	Gudmundsdóttir SL, Ballarini T, Ámundadóttir ML, et al. Clinical efficacy of a digital intervention for patients with atopic dermatitis: a prospective single⁃center study［J］. Dermatol Ther （Heidelb）, 2022,12（11）:2601⁃2611. doi: 10.1007/s13555⁃022⁃00821⁃y.
［47］	中国医师协会皮肤科医师分会. 保湿润肤类产品应用指导专家共识（2023版）［J］. 中华皮肤科杂志, 2023,56（8）:711⁃717. doi: 10.35541/cjd.20230133.
［48］	中国中西医结合学会皮肤性病专业委员会. 规范外用糖皮质激素类药物专家共识［J］. 中华皮肤科杂志, 2015,48（2）:73⁃75. doi: 10.3760/cma.j.issn.0412⁃4030.2015. 02.001.
［49］	Ang⁃Tiu CU, Meghrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials［J］. Expert Rev Clin Pharmacol, 2012,5（1）:91⁃97. doi: 10.1586/ecp.11.68.
［50］	Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: partⅠ, efficacy［J］. J Am Acad Dermatol, 2001,44（1 Suppl）:S28⁃S38. doi: 10.1067/mjd.2001.109810.
［51］	Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
［52］	Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose⁃ranging, vehicle⁃ and active⁃controlled study［J］. J Am Acad Dermatol, 2020,82（6）:1305⁃1313. doi: 10.1016/j.jaad.2020.02.009.
［53］	Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double⁃blind studies［J］. J Am Acad Dermatol, 2021,85（4）:863⁃872. doi: 10.1016/j.jaad.2021.04.085.
［54］	Bauer M, Schwameis R, Scherzer T, et al. A double⁃blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine⁃induced pruritus and UVB⁃light induced slight sunburn pain［J］. J Dermatolog Treat, 2015,26（4）:367⁃372. doi: 10.3109/09546634.2014.992384.
［55］	Tarng DC, Cho YL, Liu HN, et al. Hemodialysis⁃related pruritus: a double⁃blind, placebo⁃controlled, crossover study of capsaicin 0.025% cream［J］. Nephron, 1996,72（4）:617⁃622. doi: 10.1159/000188949.
［56］	Lysy J, Sistiery⁃Ittah M, Israelit Y, et al. Topical capsaicin⁃⁃a novel and effective treatment for idiopathic intractable pruritus ani: a randomised, placebo controlled, crossover study［J］. Gut, 2003,52（9）:1323⁃1326. doi: 10.1136/gut.52.9.1323.
［57］	Panahi Y, Davoodi SM, Khalili H, et al. Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure［J］. Singapore Med J, 2007,48（5）:392⁃395.
［58］	Macpherson LJ, Hwang SW, Miyamoto T, et al. More than cool: promiscuous relationships of menthol and other sensory compounds［J］. Mol Cell Neurosci, 2006,32（4）:335⁃343. doi: 10.1016/j.mcn.2006.05.005.
［59］	High⁃dose antihistamines for chronic spontaneous urticaria in adults［J］. Drug Ther Bull, 2018,56（4）:45⁃48. doi: 10.1136/dtb.2018.4.0614.
［60］	Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double⁃blind, placebo⁃controlled phase 3 trials［J］. Nat Med, 2023,29（5）:1180⁃1190. doi: 10.1038/s41591⁃023⁃02320⁃9.
［61］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［62］	Blauvelt A, de Bruin⁃Weller M, Gooderham M, et al. Long⁃term management of moderate⁃to⁃severe atopic dermatitis with dupilumab and concomitant topical corticosteroids （LIBERTY AD CHRONOS）: a 1⁃year, randomised, double⁃blinded, placebo⁃controlled, phase 3 trial［J］. Lancet, 2017,389（10086）:2287⁃2303. doi: 10.1016/S0140⁃6736（17）31191⁃1.
［63］	Jeon J, Wang F, Badic A, et al. Treatment of patients with chronic pruritus of unknown origin with dupilumab［J］. J Dermatolog Treat, 2022,33（3）:1754⁃1757. doi: 10.1080/09546634.2021.1880542.
［64］	Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab⁃a case series［J］. Medicines （Basel）, 2019,6（3）:72. doi: 10.3390/medicines6030072.
［65］	Wang SH, Shan Y, Li SZ, et al. Anti⁃interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1⁃year follow⁃up: a monocentric real⁃world study［J］. Front Immunol, 2023,14:1165106. doi: 10.3389/fimmu.2023.1165106.
［66］	Bai F, Li GG, Liu Q, et al. Short⁃term efficacy and safety of IL⁃17, IL⁃12/23, and IL⁃23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Immunol Res, 2019,2019:2546161. doi: 10.1155/2019/2546161.
［67］	Sbidian E, Chaimani A, Garcia⁃Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta⁃analysis［J］. Cochrane Database Syst Rev, 2017,12（12）:CD011535. doi: 10.1002/14651858.CD011535.pub2.
［68］	Thyssen JP, Yosipovitch G, Paul C, et al. Patient⁃reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2022,36（3）:434⁃443. doi: 10.1111/jdv.17813.
［69］	Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2021,157（9）:1047⁃1055. doi: 10.1001/jamadermatol. 2021.3023.
［70］	Reich K, Teixeira HD, de Bruin⁃Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate⁃to⁃severe atopic dermatitis （AD Up）: results from a randomised, double⁃blind, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10290）:2169⁃2181. doi: 10.1016/S0140⁃6736（21）00589⁃4.
［71］	Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:397⁃402. doi: 10. 1111/jdv.14738.
［72］	Sardana K, Sharath S, Khurana A. Use of tofacitinib in recalcitrant cases of chronic pruritus of unknown origin［J］. Arch Dermatol Res, 2023,315（10）:2955⁃2957. doi: 10.1007/s00403⁃023⁃02707⁃1.
［73］	van Huizen AM, Sikkel R, Caron A, et al. Methotrexate dosing regimen for plaque⁃type psoriasis: an update of a systematic review［J］. J Dermatolog Treat, 2022,33（8）:3104⁃3118. doi: 10.1080/09546634.2022.2117539.
［74］	Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta⁃analysis［J］. Cochrane Database Syst Rev, 2023,7（7）:CD011535. doi: 10.1002/14651858.CD011535.pub6.
［75］	Chu A, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis （eczema）: systematic review and network meta⁃analysis of randomized trials［J］. J Allergy Clin Immunol, 2023,152（6）:1470⁃1492. doi: 10.1016/j.jaci.2023.08.029.
［76］	Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta⁃analysis［J］. JAMA Dermatol, 2020,156（6）:659⁃667. doi: 10.1001/jamadermatol. 2020.0796.
［77］	Siegels D, Heratizadeh A, Abraham S, et al. Systemic treatments in the management of atopic dermatitis: a systematic review and meta⁃analysis［J］. Allergy, 2021,76（4）:1053⁃1076. doi: 10. 1111/all.14631.
［78］	Siepmann D, Luger TA, Ständer S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series［J］. J Dtsch Dermatol Ges, 2008,6（11）:941⁃946. doi: 10.1111/j.1610⁃0387.2008.06745.x.
［79］	Klejtman T, Beylot⁃Barry M, Joly P, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases［J］. J Eur Acad Dermatol Venereol, 2018,32（3）:437⁃440. doi: 10.1111/jdv.14646.
［80］	Bergasa NV, McGee M, Ginsburg IH, et al. Gabapentin in patients with the pruritus of cholestasis: a double⁃blind, randomized, placebo⁃controlled trial［J］. Hepatology, 2006,44（5）:1317⁃1323. doi: 10.1002/hep.21370.
［81］	Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo⁃controlled, double⁃blind trial［J］. Nephrol Dial Transplant, 2004,19（12）:3137⁃3139. doi: 10.1093/ndt/gfh496.
［82］	Mazza M, Guerriero G, Marano G, et al. Treatment of prurigo nodularis with pregabalin［J］. J Clin Pharm Ther, 2013,38（1）:16⁃18. doi: 10.1111/jcpt.12005.
［83］	Yue J, Jiao S, Xiao Y, et al. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double⁃blind study［J］. Int Urol Nephrol, 2015,47（1）:161⁃167. doi: 10.1007/s11255⁃014⁃0795⁃x.
［84］	Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k guideline on chronic pruritus［J］. Acta Derm Venereol, 2019,99（5）:469⁃506. doi: 10.2340/00015555⁃3164.
［85］	Mathur VS, Kumar J, Crawford PW, et al. A multicenter, randomized, double⁃blind, placebo⁃controlled trial of nalbuphine ER tablets for uremic pruritus［J］. Am J Nephrol, 2017,46（6）:450⁃458. doi: 10.1159/000484573.
［86］	Huang X, Xiao Y, Jing D, et al. Arsenic exposure and pruritus: evidence from observational, interventional, and mendelian randomization studies［J］. Allergy, 2023,78（6）:1585⁃1594. doi: 10.1111/all.15758.
［87］	Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus［J］. N Engl J Med, 2020,382（3）:222⁃232. doi: 10.1056/NEJMoa1912770.
［88］	Kim BS, Bissonnette R, Nograles K, et al. Phase 2 trial of difelikefalin in Notalgia paresthetica［J］. N Engl J Med, 2023,388（6）:511⁃517. doi: 10.1056/NEJMoa2210699.
［89］	Buteau A, Reichenberg J. Psychogenic pruritus and its management［J］. Dermatol Clin, 2018,36（3）:309⁃314. doi: 10. 1016/j.det.2018.02.015.
［90］	Kouwenhoven TA, van de Kerkhof P, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review［J］. J Am Acad Dermatol, 2017,77（6）:1068⁃1073.e7. doi: 10.1016/j.jaad.2017.08.025.
［91］	Kaur R, Sinha VR. Antidepressants as antipruritic agents: a review［J］. Eur Neuropsychopharmacol, 2018,28（3）:341⁃352. doi: 10.1016/j.euroneuro.2018.01.007.
［92］	Ständer S, Böckenholt B, Schürmeyer⁃Horst F, et al. Treatment of chronic pruritus with the selective serotonin re⁃uptake inhibitors paroxetine and fluvoxamine: results of an open⁃labelled, two⁃arm proof⁃of⁃concept study［J］. Acta Derm Venereol, 2009,89（1）:45⁃51. doi: 10.2340/00015555⁃0553.
［93］	Wachholz PA, Masuda PY, Pinto A, et al. Impact of drug therapy on brachioradial pruritus［J］. An Bras Dermatol, 2017,92（2）:281⁃282. doi: 10.1590/abd1806⁃4841.20175321.
［94］	Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double⁃blind trial［J］. Nephron, 1994,67（3）:270⁃273. doi: 10.1159/000187978.
［95］	Sharma D, Kwatra SG. Thalidomide for the treatment of chronic refractory pruritus［J］. J Am Acad Dermatol, 2016,74（2）:363⁃369. doi: 10.1016/j.jaad.2015.09.039.
［96］	Müller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5⁃hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo⁃controlled, double⁃blind cross⁃over trial［J］. Eur J Gastroenterol Hepatol, 1998,10（10）:865⁃870. doi: 10.1097/00042737⁃199810000⁃00010.
［97］	Yosipovitch G, Ständer S, Kerby MB, et al. Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo⁃controlled phase 2 clinical trial［J］. J Am Acad Dermatol, 2018,78（5）:882⁃891.e10. doi: 10.1016/j.jaad.2018.02.030.
［98］	Ständer S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2019,80（5）:1395⁃1402. doi: 10.1016/j.jaad.2019.01.052.
［99］	Ada S, Seçkin D, Budakoğlu I, et al. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study［J］. J Am Acad Dermatol, 2005,53（1）:149⁃151. doi: 10.1016/j.jaad.2004.12.052.
［100］	Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis⁃induced pruritus treated with ultraviolet B phototherapy: an observational case series study［J］. J Hepatol, 2012,57（3）:637⁃641. doi: 10.1016/j.jhep.2012.04.023.
［101］	Kaptanoglu AF, Oskay T. Ultraviolet B treatment for pruritus in Hodgkin′s lymphoma［J］. J Eur Acad Dermatol Venereol, 2003,17（4）:489⁃490. doi: 10.1046/j.1468⁃3083.2003.00614_15.x.
［102］	Huang D, Chen K, Zhang FR, et al. Efficacy and safety of Run Zao Zhi Yang capsule on chronic eczema: a multiple⁃center, randomized, double⁃blind, placebo⁃controlled clinical study［J］. J Dermatolog Treat, 2019,30（7）:677⁃684. doi: 10.1080/09546634.2019.1571267.
［103］	Xue W, Zhao Y, Yuan M, et al. Chinese herbal bath therapy for the treatment of uremic pruritus: meta⁃analysis of randomized controlled trials［J］. BMC Complement Altern Med, 2019,19（1）:103. doi: 10.1186/s12906⁃019⁃2513⁃9.
［104］	Stellon A. Neurogenic pruritus: an unrecognised problem? A retrospective case series of treatment by acupuncture［J］. Acupunct Med, 2002,20（4）:186⁃190. doi: 10.1136/aim.20.4. 186.
［105］	Chung BY, Um JY, Kim JC, et al. Pathophysiology and treatment of pruritus in elderly［J］. Int J Mol Sci, 2020,22（1）doi: 10.3390/ijms22010174.
［106］	Balakirski G, Novak N. Atopic dermatitis and pregnancy［J］. J Allergy Clin Immunol, 2022,149（4）:1185⁃1194. doi: 10.1016/j.jaci.2022.01.010.
［107］	Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1644⁃1659. doi: 10.1111/jdv.15709.
［108］	Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy［J］. J Am Acad Dermatol, 2014,70（3）:401.e1⁃14; quiz 415. doi: 10. 1016/j.jaad.2013.09.010.
［109］	Weber⁃Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study［J］. Reprod Toxicol, 2008,26（1）:19⁃23. doi: 10.1016/j.reprotox. 2008.05.053.
［110］	Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study［J］. J Allergy Clin Immunol, 2003,111（3）:479⁃483. doi: 10.1067/mai.2003.130.
［111］	Reggia R, Bazzani C, Andreoli L, et al. The efficacy and safety of cyclosporin A in pregnant patients with systemic autoimmune diseases［J］. Am J Reprod Immunol, 2016,75（6）:654⁃660. doi: 10.1111/aji.12514.
［112］	Pugliese D, Privitera G, Gisbert JP, et al. New drugs for the treatment of IBD during conception, pregnancy, and lactation［J］. Dig Liver Dis, 2024,56（2）:235⁃241. doi: 10.1016/j.dld. 2023.08.054.
［113］	Janssen NM, Genta MS. The effects of immunosuppressive and anti⁃inflammatory medications on fertility, pregnancy, and lactation［J］. Arch Intern Med, 2000,160（5）:610⁃619. doi: 10.1001/archinte.160.5.610.

[1]	Zheng Yaxuan, Su Huichun. Role of sweat in the pathogenesis of cholinergic urticaria [J]. Chinese Journal of Dermatology, 2025, 58(6): 573-577.
[2]	Qi-Quan CHEN Song Zhi-Qiang WANG Gang. Guidelines for the diagnosis and treatment of refractory chronic spontaneous urticaria in China （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(6): 485-496.
[3]	The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404.
[4]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[5]	Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association, Society of Integrated Rehabilitation of Skin Tumors, China Anti-Cancer Association. Expert consensus on diagnosis and treatment of pigmented nevi （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 387-395.
[6]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[7]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the diagnosis and treatment of paraneoplastic pemphigus in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 289-296.
[8]	Dong Yi, Yan Xin, Munire·Tayier, Zhang Xingqi. Application of machine learning in dermatology [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240290-e20240290.
[9]	Chen Yao, Yu Lang, Jiang Qian, Yu Huiyuan, Chen Liuqing, Chen Jinbo. Comparison of optical coherence tomography imaging features between bullous pemphigoid and pemphigus [J]. Chinese Journal of Dermatology, 2025, 58(3): 216-220.
[10]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2025, 58(3): 272-275.
[11]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline on phototherapy for vitiligo （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 197-208.
[12]	Qin Bei, Li Qinfeng. Blueberry muffin baby: advances in the etiology [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220411-e20220411.
[13]	Yuan Yongyong, Pan Meng. Advances in Hailey-Hailey Disease [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240182-e20240182.
[14]	Zhang Beilei, Song Xiuzu. Etiology and pathogenesis of sensitive scalp [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240301-e20240301.
[15]	Huang Xiaoyan, Su Juan, Chen Mingliang, Chen Xiang, Xiao Yi, Shen Minxue, . Efficacy of naloxone in improving health-related quality of life in patients with chronic arsenic exposure-related pruritus: a randomized, double-blind, placebo-controlled trial [J]. Chinese Journal of Dermatology, 2025, 58(2): 161-166.

Guidelines for the management of chronic pruritus （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［113］

Related Articles 15

Metrics

Comments

Recommended 10